Subsequent Events (Details) - Subsequent Event [Member] - DIAMIR BIOSCIENCES CORP. [Member] - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Jul. 07, 2025 |
May 31, 2025 |
Jun. 30, 2025 |
|
| Subsequent Events (Details) [Line Items] | |||
| Additional loan | $ 150,000 | ||
| Purchase warrant | $ 500,000 | ||
| Exercise price per share (in Dollars per share) | $ 0.01 | ||
| Gross proceeds | $ 4,000,000 | ||
| Received cash fees | 250,000 | ||
| Number of warrants | $ 250,000 |
| X | ||||||||||
- Definition Represent the amount of gross proceeds. No definition available.
|
| X | ||||||||||
- Definition Represent the amount of purchase warrant. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of long-term loans payable classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received for fees during the current period. This element excludes cash proceeds from license fees. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|